American Association of Individual Investors5d
Why Sangamo Therapeutics, Inc.’s (SGMO) Stock Is Down 13.07%
Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 13.07%, which has investors questioning if this is right time to ...
The Manila Times6d
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board
Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for ...
BioPharma Dive12d
Tempero Bio gets $70M to advance substance abuse treatment
The Series B round will help the Aditum Bio-backed startup fund two mid-stage clinical trials in people with alcohol and ...
Daily15d
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy
Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria.
Nasdaq15d
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...
ENDPOINTS NEWS15d
FDA ap­proves No­var­tis’ Fab­hal­ta in an­oth­er rare kid­ney dis­ease
No­var­tis’ Fab­hal­ta notched an­oth­er FDA ap­proval, this time in adults with an ul­tra-rare kid­ney dis­ease called C3 glomeru­lopa­thy.
FiercePharma16d
Novartis links music and science in corporate campaign tied to Eurovision sponsorship
Those plans are now taking shape. Novartis this week debuted a pair of videos, each featuring a company employee discussing how their musical talents align with their scientific careers, as part ...
Benzinga.com16d
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
The FDA approved Novartis' Fabhalta, making it the first and only treatment for adults with C3 glomerulopathy. Fabhalta showed sustained proteinuria reduction in Phase 3 trials, with effects seen ...
Nasdaq16d
FDA Approves Novartis' Oral Fabhalta For Treatment Of Adults With Complement 3 Glomerulopathy
(RTTNews) - Novartis AG (NVS) announced that the U.S. Food and Drug Administration has approved oral Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy to reduce ...
manilatimes16d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 - Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...